<a href="https://laohu8.com/S/COGT">Cogent Biosciences</a> Inc. Announces Positive Results from SUMMIT Trial, Plans NDA Submission for Bezuclastinib by End of 2025
Cogent Biosciences Inc. announced on July 7, 2025, that it has achieved positive top-line results from Part 2 of the SUMMIT clinical trial for bezuclastinib in patients with non-advanced systemic mastocytosis. These results demonstrate clinically meaningful improvements across primary and secondary endpoints, strengthening the company's plan to submit a new drug application to the U.S. FDA by the end of 2025. The SUMMIT trial results will be detailed at a major medical conference later this year. Additionally, Cogent Biosciences is on track to release top-line results for its ongoing PEAK and APEX trials in the latter half of 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cogent Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-155811), on July 07, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。